Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$166.5K-98.11%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- A. J. Kazimi
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 88
- Beta
- 0.10
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 0.82
Financials
Revenue
$166.5K-98.1%Net Income
$-4.12M-3976.6%EBITDA
$-3.12M-492.6%Free Cash Flow
$-1.61MEPS (diluted)
$-0.27-2800.0%Shares Outstanding (diluted)
14.98M-9.2%Operating Expenses
$3.32MCash & Debt
$3.86MReturn of Capital
$0.00Revenue by Segment (annual)
$54.01MDividend per Share
$1.50Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $44.52M | $-2.84M | $-0.19 |
| 2024 | $37.87M | $-6.48M | $-0.46 |
| 2023 | $39.55M | $-6.28M | $-0.44 |
| 2022 | $42.01M | $-5.57M | $-0.38 |
| 2021 | $35.99M | $-3.51M | $-0.24 |
| 2020 | $37.44M | $-3.34M | $-0.22 |
| 2019 | $34.39M | $-3.54M | $-0.23 |
| 2018 | $40.74M | $-6.96M | $-0.45 |
| 2017 | $41.15M | $-7.98M | $-0.50 |
| 2016 | $33.03M | $-944.7K | $-0.06 |
| 2015 | $33.52M | $731.4K | $0.04 |
| 2014 | $36.90M | $2.42M | $0.14 |
| 2013 | $32.03M | $-2.10M | $-0.11 |
| 2012 | $48.85M | $5.84M | $0.30 |
Valuation
CPIXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (3)
- Newsprnewswire.com·5h ago·Neutral
Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results Ifetroban was well tolerated in patients with systemic sclerosis NASHVILLE, Tenn., Oct. 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, announces top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for patients with systemic sclerosis ("SSc").
View source ↗ - Newsprnewswire.com·4d ago·Positive
…LS ANNOUNCES NATIONAL CALL TO PRESENT AN UPDATE ON ITS IFETROBAN DMD PROGRAM NASHVILLE, Tenn., Oct. 19, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, announced today that it will provide an update on its ifetroban product candidate in development as a potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy ("DMD").
View source ↗ - Newsdefenseworld.net·72d ago·Negative
Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Passes Above Two Hundred Day Moving Average – Should You Sell? Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX - Get Free Report) passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $4.87 and traded as high as $8.15. Cumberland Pharmaceuticals shares last traded at $7.96, with a volume of 79,334 shares traded. Analysts Set New Price Targets CPIX has
View source ↗
Earnings
Tue, Nov 3(in 10 days)
Consensus estimate $-0.13 per share
Typical surprise +67.8% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$-0.20 vs $-0.13miss
- Tue, May 5$-0.13 vs $-0.13beat
- Tue, Mar 3$-0.01 vs $-0.13beat
- Tue, Nov 4$-0.06 vs $-0.13beat
- Tue, May 6$0.16 vs $-0.01beat
- Tue, Mar 4$-0.02 vs $-0.11beat
Estimates and results for CPIX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CPIX officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CPIX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.